AHA Scientific Sessions 2026 Abstract · Nov 2, 2026

Association of Glucagon-Like Peptide-1 Receptor Agonist Therapy with Risk of Recurrent Myocardial Infarction Following Acute Myocardial Infarction

By Asemi S, Williams L, Aman N

Background: Patients who survive acute myocardial infarction (MI) remain at elevated risk for recurrent ischemic events despite contemporary medical therapy. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated cardiovascular benefit in multiple patient populations, though their impact on recurrent MI following index infarction remains incompletely characterized. Methods: We performed a retrospective propensity score-matched cohort study using the TriNetX Global Collaborative Network. Matching was performed on 42 characteristics. Adult patients with prior MI who initiated GLP-1 receptor agonist therapy within 1 year of index MI were compared against matched post-MI controls without GLP-1 exposure. Outcomes were assessed at 5-year follow-up. Subgroup analyses were performed for tirzepatide, semaglutide, dulaglutide, and liraglutide. Because TriNetX permits matching between up to two cohorts at a time, each medication subgroup was matched against a separately derived control cohort. The primary outcome was recurrent MI. Risk ratios (RRs) and hazard ratios (HRs) with 95% confidence intervals were calculated. Results: GLP-1 receptor agonist therapy was associated with significantly reduced recurrent MI risk compared with matched controls. Among individual agents, tirzepatide demonstrated the largest observed association with reduced recurrent MI risk, followed by semaglutide. Dulaglutide demonstrated moderate but statistically significant reductions in recurrent MI risk, while liraglutide demonstrated smaller but still favorable associations. Detailed HR and RR for all cohorts and follow-up intervals are presented in the accompanying tables. Conclusions: GLP-1 receptor agonist therapy initiated within 1 year following acute MI was associated with significantly reduced recurrent MI risk at 5-year follow-up. Tirzepatide demonstrated the strongest observed association, followed by semaglutide. These findings support further prospective investigation into GLP-1 and GIP-based therapies for secondary cardiovascular prevention following MI.

doi.org/10.1161/circ.154.suppl_1.17572Interventions

AgingResearch.News